Jardiance (empagliflozin) 25 mg is a medication used to manage type 2 diabetes by belonging to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. The primary mechanism of action of Jardiance involves the kidneys and glucose regulation.
Here's how Jardiance 25 mg works:
Inhibition of SGLT2:
Jardiance works by inhibiting the action of a specific protein called SGLT2 in the kidneys. SGLT2 is responsible for reabsorbing glucose (sugar) from the urine back into the bloodstream.
Increased Glucose Excretion:
By inhibiting SGLT2, Jardiance prevents the reabsorption of glucose by the kidneys. This leads to an increased excretion of glucose through the urine, lowering the overall blood sugar levels.
Reduced Blood Sugar Levels:
As more glucose is excreted in the urine, the concentration of glucose in the bloodstream decreases. This results in improved blood sugar control for individuals with type 2 diabetes.
Additional Cardiovascular Benefits:
Beyond its impact on blood sugar levels, Jardiance has demonstrated cardiovascular benefits. Clinical studies have shown a reduction in the risk of cardiovascular events, including heart attack and stroke, in individuals with type 2 diabetes who take Jardiance.
Lowering Blood Pressure:
Jardiance may also lead to a modest reduction in blood pressure, contributing to its overall cardiovascular benefits.